Oncternal Therapeutics, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
MRKMerck & Co., Inc. -0.06%81.120.7%$1566.02m
JNJJohnson & Johnson 0.19%163.710.7%$997.82m
PFEPfizer Inc. 0.77%43.190.9%$901.42m
ABBVAbbVie, Inc. 0.42%109.221.9%$661.78m
BMYBristol-Myers Squibb Co. -0.38%57.591.0%$625.23m
LLYEli Lilly & Co. 1.07%243.751.1%$585.84m
AZNAstraZeneca Plc 0.93%61.791.0%$310.35m
NVSNovartis AG 0.31%84.930.2%$174.90m
GSKGlaxoSmithKline Plc 0.58%39.780.2%$162.05m
AVIRAtea Pharmaceuticals, Inc. -0.16%12.730.3%$125.28m
RGENRepligen Corp. 1.55%274.956.8%$113.28m
NVONovo Nordisk A/S 1.51%105.990.1%$89.92m
VTRSViatris, Inc. -0.50%13.940.0%$87.91m
SNYSanofi 1.44%49.920.2%$70.53m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 2.27%139.980.0%$52.50m

Company Profile

Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Cirmtuzumab, TK216, and ROR1 CAR-T. The company was founded by David F. Hale and James B. Breitmeyer in 1997 and is headquartered in San Diego, CA.